Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin

2013 ◽  
Vol 25 (6) ◽  
pp. 467-e363 ◽  
Author(s):  
S. Bickelhaupt ◽  
S. Pazahr ◽  
N. Chuck ◽  
I. Blume ◽  
J. M. Froehlich ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
C Reactive Protein ◽  
Bowel Motility ◽  
Small Bowel Motility ◽  
Reactive Protein

scholarly journals Relationship between MRI quantified small bowel motility and abdominal symptoms in Crohn’s disease patients—a validation study

2018 ◽  
pp. 20170914 ◽  
Author(s):  
Ruaridh M Gollifer ◽  
Alex Menys ◽  
Jesica Makanyanga ◽  
Carl AJ Puylaert ◽  
Frans M Vos ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Validation Study ◽  
Bowel Motility ◽  
Small Bowel Motility ◽  
Abdominal Symptoms

Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn’s disease

2014 ◽  
Vol 49 (9) ◽  
pp. 1084-1090 ◽  
Author(s):  
Charlotte M. Höög ◽  
Lars-Åke Bark ◽  
Olle Broström ◽  
Urban Sjöqvist
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Fecal Calprotectin ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Endoscopic Findings

Su1934 A DIRECT COMPARISON OF FECAL CALPROTECTIN, HIGH-SENSITIVITY C-REACTIVE PROTEIN, AND LEUCIN-RICH ALPHA-2 GLYCOPROTEIN IN DETECTING ACTIVITY OF SMALL BOWEL CROHN'S DISEASE

2020 ◽  
Vol 158 (6) ◽  
pp. S-708-S-709
Author(s):  
Kunio Asonuma ◽  
Shintaro Sagami ◽  
Hiroki Kiyohara ◽  
Mao Matsubayashi ◽  
Hiromu Morikubo ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
High Sensitivity ◽  
Fecal Calprotectin ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals P138 Platelet-to-lymphocyte ratio index: a reliable tool for non-invasive assessment of endoscopic activity in small bowel Crohn’s Disease

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S225-S225
Author(s):  
V Macedo Silva ◽  
M Freitas ◽  
S Xavier ◽  
T Cúrdia Gonçalves ◽  
P Boal Carvalho ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Fecal Calprotectin ◽  
Mucosal Healing ◽  
C Reactive Protein ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Reactive Protein ◽  
Non Invasive

Abstract Background The platelet-to-lymphocyte ratio (PLR) index has been a recent focus of investigation as a reliable marker of inflammation. This score was recently shown to have a good accuracy upon predicting endoscopic remission in patients with colonic Crohn’s Disease (CD). We aimed to assess the discriminative power of PLR index in patients with isolated small bowel CD. Methods Single center study of consecutive patients with isolated small bowel CD (L1 ± L4 disease according to Montreal classification) who underwent small bowel capsule endoscopy (SBCE) for assessment of endoscopic activity between January 2019 and December 2020. Only complete SBCEs were considered. CD endoscopic activity was classified according to the Lewis score (LS) value. Complete blood count, C-reactive protein and fecal calprotectin values were collected within 1 month of SBCE. Results Final sample included 49 patients, 35 (71.4%) of them females, with a mean age of 35.1±11.8 years. SBCE reported mucosal healing (LS<135) in 30.6% of the patients; mild activity (135≤LS<790) in 42.9% and moderate-to-severe activity (LS≥790) in 26.5% of the patients. PLR index positive correlation with LS was significant and moderate (k=0.597; p<0.001). This correlation was stronger than the one seen between fecal calprotectin (k=0.525; p=0.001) or C-reactive protein (k=0.321; p=0.029) and the LS score. In particular, PLR index presented an excellent accuracy for predicting patients with a moderate-to-severe endoscopic activity (AUC=0.908; 95%CI=0.816–0.999; p<0.001), with an optimal cut-off of PLR above 157 (sensitivity 92.3%; specificity 82.9%). The accuracy for prediction of mucosal healing was good (AUC=0.743; 95%CI=0.600–0.887; p=0.007), with an optimal cut-off of PLR below 126 (sensitivity 66.7%; specificity 80.0%). Conclusion PLR index demonstrated an excellent acuity for predicting patients with moderate to severe disease in small bowel CD. Moreover, it also demonstrated good acuity for predicting mucosal healing on this set of patients. These results come from a significant correlation of PLR index with endoscopic activity in small bowel CD. Our findings establish this index as a promising and easy-to-apply tool for non-invasive and regular follow-up of patients with small bowel CD.

Quantification, validation, and follow-up of small bowel motility in Crohn's disease

2015 ◽  
Author(s):  
Juan J. Cerrolaza ◽  
Jennifer Q. Peng ◽  
Nabile M. Safdar ◽  
Laurie Conklin ◽  
Raymond Sze ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Bowel Motility ◽  
Small Bowel Motility

Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease

2013 ◽  
Vol 28 (5) ◽  
pp. 829-833 ◽  
Author(s):  
Li Yang ◽  
Zhi-Zheng Ge ◽  
Yun-Jie Gao ◽  
Xiao-Bo Li ◽  
Jun Dai ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Disease Activity ◽  
Capsule Endoscopy ◽  
Clinical Disease ◽  
C Reactive Protein ◽  
Clinical Disease Activity ◽  
Reactive Protein ◽  
Scoring Index

Differentiation between active and chronic Crohn's disease using MRI small-bowel motility examinations — Initial experience

2013 ◽  
Vol 68 (12) ◽  
pp. 1247-1253 ◽  
Author(s):  
S. Bickelhaupt ◽  
J.M. Froehlich ◽  
R. Cattin ◽  
N. Patuto ◽  
R. Tutuian ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Initial Experience ◽  
Bowel Motility ◽  
Small Bowel Motility

scholarly journals Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease

2019 ◽  
Vol 111 (1) ◽  
pp. 131-140
Author(s):  
Asseel Khalaf ◽  
Caroline L Hoad ◽  
Alex Menys ◽  
Adam Nowak ◽  
Shellie Radford ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Gut Hormones ◽  
Standard Test ◽  
Gut Peptides ◽  
Bowel Motility ◽  
Small Bowel Motility ◽  
Mri Scans ◽  
Glucagon Like Peptide 1

ABSTRACT Background Crohn's disease (CD) patients suffer postprandial aversive symptoms, which can lead to anorexia and malnutrition. Changes in the regulation of gut hormones and gut dysmotility are believed to play a role. Objectives This study aimed to investigate small-bowel motility and gut peptide responses to a standard test meal in CD by using MRI. Methods We studied 15 CD patients with active disease (age 36 ± 3 y; BMI 26 ± 1 kg/m 2) and 20 healthy volunteers (HVs; age 31 ± 3 years; BMI 24 ± 1 kg/m 2). They underwent baseline and postprandial MRI scans, symptom questionnaires, and blood sampling following a 400-g soup meal (204 kcal). Small-bowel motility, other MRI parameters, and glucagon-like peptide-1 (GLP-1), polypeptide YY (PYY), and cholecystokinin peptides were measured. Data are presented as means ± SEMs. Results HVs had significantly higher fasting motility indexes [106 ± 13 arbitrary units (a.u.)], compared with CD participants (70 ± 8 a.u.; P ≤ 0.05). Postprandial small-bowel water content showed a significant time by group interaction (P < 0.05), with CD participants showing higher levels from 210 min postprandially. Fasting concentrations of GLP-1 and PYY were significantly greater in CD participants, compared with HVs [GLP-1, CD 50 ± 8 µg/mL versus HV 13 ± 3 µg/mL (P ≤ 0.0001); PYY, CD 236 ± 16 pg/mL versus HV 118 ± 12 pg/mL (P ≤ 0.0001)]. The meal challenge induced a significant postprandial increase in aversive symptom scores (fullness, distention, bloating, abdominal pain, and sickness) in CD participants compared with HVs (P ≤ 0.05). Conclusions The decrease in fasting small-bowel motility noted in CD participants can be ascribed to the increased fasting gut peptides. A better understanding of the etiology of aversive symptoms in CD will facilitate identification of better therapeutic targets to improve nutritional status. This trial was registered at clinicaltrials.gov as NCT03052465.

Sign in / Sign up

Export Citation Format

Share Document